Pfizer reported third-quarter 2026 results on November 3 that exceeded the company’s expectations. The company’s commercial performance globally and continued financial discipline led to it raising ...

Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced ...

The seasons are changing and the weather is getting cooler, but our social media round-up is hot off the presses. As usual, we are sharing the latest and greatest updates from the last month. In ...

MagnetisMM-32 is an open-label, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of ELREXFIO monotherapy versus investigator’s choice among three standard-of-care regimens ...

About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

As the understanding of obesity science evolves, focus is shifting from simply reducing body weight to treating obesity as a complex, chronic disease affecting almost every system of the body. Along ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease ...

Over millions of years, humans got remarkably good at storing excess energy as fat. To survive perilous stretches of scarcity and famine, our brains evolved to view calorie-dense foods as highly ...

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option NEW ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...